Newswire (Published: Monday, June 19, 2017, Received: Thursday, June 15, 2017, 12:12:34 PM CDT)

Word Count: 576

By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news reporting originating from Bethesda, Maryland, by NewsRx correspondents, research stated, "Prostate cancer is the most common solid tumor malignancy in men worldwide. Treatment with surgery and radiation can be curative in organ-confined disease."

Our news editors obtained a quote from the research from National Cancer Institute, "Unfortunately, about one third of men develop biochemically recurrent disease based only on rising prostate-specific antigen (PSA) in the absence of visible disease on conventional imaging. For these patients with biochemical recurrent prostate cancer, there is no uniform guideline for subsequent management. Based on available data, it seems prudent that biochemical recurrent prostate cancer should initially be evaluated for salvage radiation or prostatectomy, with curative intent. In selected cases, high-intensity focused ultrasound and cryotherapy may be considered in patients that meet very narrow criteria as defined by non-randomized trials. If salvage options are not practical or unsuccessful, androgen deprivation therapy (ADT) is a standard option for disease control. While some patients prefer ADT to manage the disease immediately, others defer treatment because of the associated toxicity. In the absence of definitive randomized data, patients may be followed using PSA doubling time as a trigger to initiate ADT. Based on retrospective data, a PSA doubling time of less than 3-6 months has been associated with near-term development of metastasis and thus could be used signal to initiate ADT. Once treatment is begun, patients and their providers can choose between an intermittent and continuous ADT strategy. The intermittent approach may limit side effects but in patients with metastatic disease studies could not exclude a 20% greater risk of death. In men with biochemical recurrence, large studies have shown that intermittent therapy is non-inferior to continuous therapy, thus making this a reasonable option. Since biochemically recurrent prostate cancer is defined by technological limitations of radiographic detection, as new imaging (i.e., PSMA) strategies are developed, it may alter how the disease is monitored and perhaps managed. Furthermore, patients have no symptoms related to their disease and thus many prefer options that minimize toxicity. For this reason, herbal agents and immunotherapy are under investigation as potential alternatives to ADT and its accompanying side effects."

According to the news editors, the research concluded: "New therapeutic options combined with improved imaging to evaluate the disease may markedly change how biochemically recurrent prostate cancer is managed in the future."

For more information on this research see: Management Options for Biochemically Recurrent Prostate Cancer. Current Treatment Options in Oncology, 2017;18(5):3-21. Current Treatment Options in Oncology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Current Treatment Options in Oncology - www.springerlink.com/content/1527-2729/)

The news editors report that additional information may be obtained by contacting W.L. Dahut, National Cancer Institute, Genitourinary Malignancies Branch, Center Canc Res, National Institutes of Health, Bethesda, MD 20892, United States. Additional authors for this research include R.A. Madan and F. Fakhrejahani (see also Oncology - Prostate Cancer).

Keywords for this news article include: Bethesda, Maryland, United States, North and Central America, Chemicals, Article Review, Risk and Prevention, Prostate-Specific Antigen, Enzymes and Coenzymes, Prostatic Neoplasms, Prostate Cancer, Biochemicals, Biochemistry, Oncology, Therapy, National Cancer Institute.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

National Cancer Institute
National Institutes of Health

Industries

Biotechnology
      Biopharmaceuticals
            Immunotherapeutics
Pharmaceuticals
      Biopharmaceuticals
            Immunotherapeutics

Places

Central America
North America
United States
Americas
Maryland
New York
Bethesda
New York City

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies